| 名称 | 获配股数 | 占全球发售 | 占上市后总股本 | 锁定期 |
|---|---|---|---|---|
| Athos Asia Event Driven Master Fund | 0 | 3.05% | — | 6个月 |
| Golden Valley Global Limited | 0 | 1.52% | — | 6个月 |
| Hankang Biotech Fund I, L.P. | 0 | 3.05% | — | 6个月 |
| Matthews Asia Funds | 0 | 7.01% | — | 6个月 |
| Octagon Investments Master Fund LP | 0 | 1.83% | — | 6个月 |
| Orient Sun Rise Global Superior Choice SPC | 0 | 3.05% | — | 6个月 |
| Rock Springs Capital Master Fund LP | 0 | 3.05% | — | 6个月 |
| Tiger Pacific Master Fund LP | 0 | 4.57% | — | 6个月 |
| Vivo Funds | 0 | 7.62% | — | 6个月 |
| WT Investment Management | 0 | 3.05% | — | 6个月 |
| 妙城集团有限公司 | 0 | 1.52% | — | 6个月 |
| 中国国有企业结构调整基金股份有限公司 | 0 | 10.67% | — | 6个月 |
本页展示 诺诚健华医药有限公司 - B(09969)的打新中签分析:一手中签率、甲乙组中签分布、超额认购倍数、暗盘与首日表现。数据来自港交所配发结果公告。中签率的计算方式与回拨规则见港股中签率怎么算。

